Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosuzumab reduce fracture risk after menopause.

1. Use of bisphosphonates, denosumab, abaloparatide, teriparatide, and romosuzumab is associated with reduced clinical fractures in postmenopausal osteoporotic patients. 2. Abaloparatide and teriparatide may increase the risk of adverse events associated with withdrawal. Directory rating level: 1 (Excellent) Study rundown: Osteoporosis results in weaker bones and an increased susceptibility to fractures. By standard definition, it … Read more

Adagrasib provides antitumor activity against metastatic KRAS G12C-mutated colorectal cancer as monotherapy and in combination with cetuximab.

1. The overall tumor response to monotherapy with adagrasib was 23% and 46% in combination with cetuximab. 2. The median progression-free survival was 5.6 months on adagrasib monotherapy and 6.9 months on combination therapy with cetuximab. The level of classification of evidence: 2 (good) Study rundown: An oncogene homolog of the Kirsten rat sarcoma virus … Read more